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Although plasma neutrophil gelatinase-associated lipocalin
(NGAL) is a promising biomarker for early detection of acute
kidney injury, its ability to predict recovery is unknown. Using
RIFLE criteria to define kidney injury, we tested whether
higher plasma NGAL concentrations on the first day of
RIFLE-F would predict failure to recover in a post hoc analysis
of a multicenter, prospective, cohort study of patients with
community-acquired pneumonia. Recovery was defined as
alive and not requiring renal replacement therapy during
hospitalization or having a persistent RIFLE-F classification at
hospital discharge. Median plasma NGAL concentrations
were significantly lower among the 93 of 181 patients who
recovered. Plasma NGAL alone predicted failure to recover
with an area under the receiver operating characteristic
curve of 0.74. A clinical model using age, serum creatinine,
pneumonia severity, and nonrenal organ failure predicted
failure to recover with area under the curve of 0.78.
Combining this clinical model with plasma NGAL
concentrations did not improve prediction. The
reclassification of risk of renal recovery, however,
significantly improved by 17% when plasma NGAL was
combined with the clinical model. Thus, in this cohort of
patients with pneumonia-induced severe acute kidney
injury, plasma NGAL appears to be a useful biomarker
for predicting renal recovery.
Kidney International (2011) 80, 545–552; doi:10.1038/ki.2011.160;
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Sepsis is a leading cause of acute kidney injury (AKI) in
hospitalized patients,1–5 and development of AKI is asso-
ciated with increased risk of death.3,5 Recent studies of
patients with AKI in which sepsis was the main contributing
factor for AKI demonstrated that a large number of survivors
failed to recover renal function. First, the Beginning and
Ending Supportive Therapy for the kidney study showed that
13.8% of patients with severe AKI require renal replacement
therapy at hospital discharge.1 Second, the Acute Renal
Failure Trial Network study revealed that only 16% of
participants were alive and free of renal replacement therapy
by hospital discharge, and only 25% by day 60.6 These
findings emphasize the need for exploring interventions to
improve outcomes following AKI.
However, in order to design interventions for AKI, it is
important to distinguish patients at risk for failure to recover
kidney function from those who are likely to spontaneously
recover renal function. Such early risk stratification has
important therapeutic implications such as to enroll a
homogenous group of patients in clinical trials of AKI, to
determine the timing of initiation of renal replacement
therapy in those with severe AKI, and withdraw care in those
who are likely to have poor prognosis. However, existing
clinical severity scores for AKI7–12 have neither high levels
of discrimination nor calibration to predict renal recovery.13
On the other hand, emerging newer biomarkers of AKI could
aid in risk stratification analogous to biomarkers of
cardiovascular disease.14,15
Neutrophil gelatinase-associated lipocalin (NGAL) is
emerging as an important biomarker for early detection of
AKI in various settings,16–31 including sepsis-induced AKI,24
and would be a logical choice to evaluate for prediction of
recovery. In addition, our previous work has suggested that
plasma interleukin (IL)-6, a proinflammatory molecule, was
strongly associated with sepsis-induced AKI.32 However,
neither plasma NGAL (pNGAL) nor IL-6 has been evaluated
as a marker of outcome following AKI. In the present
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analysis, we examined whether pNGAL or IL-6 are
useful biomarkers for predicting recovery from AKI in a
multicenter, prospective study of patients with community-
acquired pneumonia. We chose community-acquired
pneumonia because it is a leading cause of AKI and a
common infectious cause of hospitalization.33
Using the widely validated Risk, Injury, Failure, Loss, and
End-stage Kidney Disease (RIFLE) criteria to define AKI, we
performed the following analyses. First, among patients
with severe AKI (RIFLE-F), we performed an outcome-
stratified analysis of baseline characteristics of patients who
recovered renal function from those who did not. Recovery
was defined as alive and neither requiring renal replacement
therapy during hospitalization nor having persistent RIFLE-F
at hospital discharge. Second, we examined differences in
pNGAL and IL-6 concentration by recovery status. Third,
we examined whether pNGAL predicted failure to recover
after adjusting for differences in demographics, severity of
illness, process of care, and within the strata of risk categories
for nonrecovery. Fourth, we assessed the contribution of
pNGAL to a clinical model in reclassifying recovery using
net reclassification index (NRI) and integrated discrimina-
tion improvement (IDI).
RESULTS
Participant characteristics and hospital course by recovery
Of the 1836 subjects with community-acquired pneumonia,
631 developed AKI.32 We selected a subset of 189 patients
(30%) who met the RIFLE-F criteria. Two patients who
received chronic dialysis before study enrollment and 6
patients in whom renal replacement therapy status during
hospitalization was unknown were excluded. Of the 181
patients with severe AKI who formed the analysis cohort, 93
subjects (51.4%) had renal recovery (Figure 1). Table 1 shows
the baseline characteristics stratified by recovery status.
Subjects who did not recover were likely to be older, had
higher serum creatinine and blood urea nitrogen, and had
more severe pneumonia. Patients who did not recover
developed more severe nonrenal organ dysfunction during
hospitalization.
Table 2 shows the hospital course and outcomes by
recovery status. The proportions of patients who
were admitted to intensive care unit, received mechanical
ventilation, and intensive care unit length of stay were
similar. However, subjects who did not recover from AKI
were more likely to stay in the hospital shorter than recovery
group. This apparently shorter duration of stay among
those who did not recover was mainly because of higher
hospital mortality among those who did not recover. Patients
who did not recover, however, also incurred higher 30-,
60-, and 90-day mortality compared with those who did
recover.
Biomarker concentration by recovery
Median pNGAL concentration on the first day of RIFLE-F
was significantly lower in the recovery group: recovery vs
nonrecovery 165 ng/ml (interquartile range (IQR) 113–266)
vs 371 ng/ml (IQR 201–519), Po0.001 (Figure 2). Non-
survivors of AKI had higher median pNGAL concentra-
tion compared with survivors: nonsurvivor vs survivor,
409.5 ng/ml (IQR 201–588) vs 207 ng/ml (IQR 127–381),
Po0.001. Similarly, we also found a higher median pNGAL
concentration among those with persistent RIFLE-F
(308 ng/ml, IQR 185.5–490) compared with those without
(203.5 ng/ml, IQR 122.5–377) (P¼ 0.005). However, pNGAL
concentration among those with and without renal replace-
ment therapy was not different (404 ng/ml (IQR 202–522) vs
210 ng/ml (IQR 127–381), P¼ 0.137). Finally, we restricted
our analysis only to survivors (n¼ 138) and pNGAL
concentration was again significantly lower in those who
recovered: recovery vs nonrecovery (165 ng/ml (IQR
113–266) vs 302 ng/ml (IQR 200–466), Po 0.001).
We found no difference in plasma IL-6 concentration on
the first day of RIFLE-F between the two groups: recovery vs
nonrecovery 3.6 (IQR 2.2–4.5) vs 3.9 (IQR 2.5–5.1) log ng/ml,
P¼ 0.20. There was also a poor correlation between pNGAL
and IL-6 (correlation coefficient¼ 0.31).
Prediction of renal recovery
Table 3 lists the derived sensitivities, specificities, and
predictive values for pNGAL at the cutoff concentrations
that provided the maximum summation of sensitivity and
specificity. The sensitivity and specificity were optimal at the
257 ng/ml cutoff, and area under the curve (AUC) was 0.74
(95% confidence interval (CI) 0.66–0.81; Figure 3). Plasma
NGAL only modestly predicted death (AUC 0.71, 95% CI
0.61–0.80), requirement of renal replacement therapy (AUC
0.62, 95% CI 0.45–0.81), and persistent RIFLE-F (AUC 0.63,
95% CI 0.54–0.72). Of the survivors (n¼ 138), pNGAL
predicted failure to recover renal function with AUC of 0.71
(95% CI 0.61–0.81).
Genetic and Inflammatory
Markers of Sepsis study
cohort (n = 1836)
AKI
(n = 631)
No AKI
(n = 1205)
Chronic dialysis (n = 2)
Unknown dialysis status (n = 6)
RIFLE-F
(n = 189)
RIFLE-R or-I
(n = 442)
Recovery
(n = 93)
Nonrecovery
(n = 88)
Figure 1 | Subject disposition for the Genetic and
Inflammatory Markers of Sepsis study cohort. AKI, acute
kidney injury; RIFLE, Risk, Injury, Failure, Loss, and
End-stage Kidney Disease.
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Table 4 shows the univariable and multivariable analyses
to predict renal recovery. When adjusted for differences in
age, serum creatinine, pneumonia severity index and
nonrenal SOFA (Sequential Organ Failure Assessment) score,
pNGAL independently predicted failure to recover renal
function (odds ratio¼ 2.02, 95% CI 1.03–3.31, P¼ 0.016).
These results remained unchanged when pneumonia severity
index score was excluded from the model (data not shown).
In order to assess the discriminatory characteristics of
pNGAL along with the clinical variables on nonrecovery, we
performed a stepwise analysis combining pNGAL with
clinical variables (Table 5). The clinical model comprising
age, serum creatinine, pneumonia severity index score, and
maximum nonrenal SOFA score (Figure 3) only modestly
predicted failure to recover from AKI with AUC of 0.78
(0.71–0.85). However, addition of pNGAL to the clinical
model did not significantly improve discrimination (com-
bined AUC¼ 0.80, 95% CI 0.73–0.87; P¼ 0.22).
Reclassification of recovery by NGAL
We also assessed the capability of pNGAL to ‘reclassify’ the
degree of risk of recovery and nonrecovery. Based on the
Table 1 | Patient characteristics by renal recovery
No. (%)
Characteristic Recovery (n=93) Nonrecovery (n=88) P-value
Age, mean (s.d.), years 67.9 (15.6) 72.9 (14.9) 0.009
Male gender 48 (51.6) 53 (60.2) 0.24
White race 75 (80.7) 74 (84.1) 0.54
Baseline creatinine, mean (s.d.), mg/dl 0.93 (0.19) 1.03 (0.71) 0.65
Serum creatinine on the first day of RIFLE-F,a mean (s.d.), mg/dl 1.75 (1.87) 3.14 (2.8) o0.001
BUN on day 1, mean (s.d.), mg/dl 29.26 (17.87) 40.27 (23.66) 0.001
BUN on the first day of RIFLE-F, mean (s.d.), mg/dl 29.09 (19.17) 44.53 (26.91) o0.001
Previous antibiotic use 19 (20.43) 12 (13.64) 0.23
Severe sepsis on day 1b 57 (61.29) 60 (68.18) 0.33
Pneumonia severity index on day 1,c mean (s.d.) 117.12 (37.94) 133.27 (39.86) 0.005
Pneumonia severity index class
I and II 16 (17.2) 8 (9.1) 0.43
III 14 (15.1) 15 (17)
IV 43 (46.2) 42 (47.7)
V 20 (21.5) 23 (26.1)
APACHE III score on day 1,d mean (s.d.) 48.4 (16.4) 52.4 (18) 0.22
Charlson comorbidity index,e mean (s.d.) 1.67 (1.96) 1.93 (1.96) 0.35
Maximum nonrenal SOFA score,f mean (s.d.) 4.35 (2.91) 5.45 (3.56) 0.04
Nonrenal SOFA score on day 1,g mean (s.d.) 2.68 (2.18) 2.83 (2.09) 0.49
Leukocyte count of the day of RIFLE-F, mean (s.d.) 15,480 (9410) 18,240 (11,860) 0.58
Abbreviations: APACHE, acute physiology and chronic health evaluation; BUN, blood urea nitrogen; RIFLE, Risk, Injury, Failure, Loss, and End-stage Kidney Disease;
SOFA, sequential organ failure assessment.
aFor severity of AKI, patients were classified according to the maximum RIFLE stage (risk, injury, or failure) reached during the entire hospitalization as proposed by the Acute
Dialysis Quality Initiative.43
bDefined as sepsis plus acute organ dysfunction according to 2001 international consensus criteria for severe sepsis.46
cPneumonia Severity Index was measured according to criteria by Fine et al.42
dAPACHE III score assessed on first hospital day regardless of whether subject was admitted to intensive care unit (ICU) or not.7
eAccording to the method of Charlson et al.45
fCumulative SOFA score, excluding the renal part, assessed on the first 7 days of hospital admission according to the method of Vincent et al.8
gSOFA score, excluding the renal part, assessed on the first day of hospital admission according to the method of Vincent et al.8
Table 2 | Hospital course and outcomes by renal recovery
No (%)
Characteristic Recovery (n=93) Nonrecovery (n=88) P-value
ICU admission 18 (19.4) 13 (14.8) 0.41
Mechanical ventilation 35 (37.6) 46 (52.3) 0.05
Length of stay in ICU, mean (s.d.) 5.6 (5.5) 5.4 (6.0) 0.38
Length of stay in hospital, mean (s.d.) 14.7 (7.6) 11.6 (7.1) 0.003
Received renal replacement therapy in the hospital 0 14 (15.9) o0.001
Persistent RIFLE-F at hospital discharge 0 60 (68.2) o0.001
Mortality
Hospital 0 43 (48.9) o0.001
30-day 4 (4.3) 42 (47.7) o0.001
60-day 9 (9.7) 49 (55.7) o0.001
90-day 12 (12.9) 49 (55.7) o0.001
Abbreviations: ICU, intensive care unit; RIFLE, Risk, Injury, Failure, Loss, and End-stage Kidney Disease.
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clinical prediction model (Table 5), subjects were categorized
into pre-specified ‘low’, ‘intermediate’, and ‘high’ risk of
nonrecovery (Table 6) using cutoffs of o30%, 30 to 60%,
and 460%, respectively.34 We then compared the propor-
tions of reclassified subjects across each of these three risk
groups when pNGAL was added to the clinical prediction
model. Among 85 patients who did not recover from AKI,
10.6% were reclassified as increased risk of nonrecovery when
pNGAL was added to the clinical prediction model and 8.2%
were reclassified as lower risk. Among 83 patients who
recovered from AKI, 8.4% were reclassified as increased risk
for recovery whereas 12% were reclassified as lower risk for
recovery. There was no overall significant improvement in
reclassification among recovery and non recovery when
pNGAL was combined with clinical model (NRI¼ 5.96%,
P¼ 0.38). However, using the relative IDI, the reclassification
of risk of recovery improved by 17.1% when pNGAL was
combined with clinical model (P¼ 0.01).
DISCUSSION
In this study, we found that patients who did not recover
from an episode of AKI in the setting of community-acquired
pneumonia were older, and had higher serum creatinine and
severity of illness during hospitalization. Plasma NGAL
concentration was significantly higher in those who failed
to recover and had a fair predictive value. A pNGAL level of
257 ng/ml predicted failure to recover with a sensitivity of
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Figure 2 |Plasma neutrophil gelatinase-associated lipocalin
(NGAL) concentration stratified by recovery. Values are
displayed as box-plot summaries with Po0.05 denoting statistical
significance. The vertical box represents the 25th percentile
(bottom line), median (middle line), and 75th percentile (top line)
values, whereas the whiskers represent the maximum and
minimum values.
Table 3 | Plasma NGAL concentration at various cutoff values
to predict failure to recover renal function
pNGAL cutoff (ng/ml) Sensitivity Specificity PPV NPV
125 0.91 0.33 0.58 0.77
257 0.68 0.75 0.73 0.70
393 0.47 0.90 0.83 0.63
Abbreviations: NPV, negative predictive value; pNGAL, plasma neutrophil gelatinase-
associated lipocalin; PPV, positive predictive value.
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pNGAL only 0.74 (0.66–0.81)
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Figure 3 | The area under the curve (AUC) for prediction of
failure to recover renal function: plasma neutrophil
gelatinase-associated lipocalin (pNGAL) alone (gray solid
line), a clinical prediction model (black solid line), and a
combined model (dotted line). Clinical predictors included age,
serum creatinine, pneumonia severity index, and maximum
nonrenal Sequential Organ Failure Assessment (SOFA) score.
Table 4 | Analysis of predictors of failure to recover renal function
Characteristic Odds ratio (95% CI) (unadjusted) P-value Odds ratio (95% CI) (adjusted) P-value
Age (per 5 years) 1.11 (1.01–1.23) 0.03 1.09 (0.96–1.24) 0.20
Creatinine on the first day of RIFLE-F 1.47 (1.18–1.84) o0.001 1.32 (1.07–1.64) 0.011
PSI on day 1 (per 10 points) 1.12 (1.03–1.21) 0.007 0.99 (0.90–1.10) 0.9039
Maximum nonrenal SOFA score (per 2 points) 1.23 (1.03–1.48) 0.025 1.37 (1.09–1.74) 0.0078
pNGAL (per 300 ng/ml) 3.31 (1.82–4.46) o0.001 2.02 (1.03–3.31) 0.0155
Abbreviations: CI, confidence interval; pNGAL, plasma neutrophil gelatinase-associated lipocalin; PSI, pneumonia severity index; RIFLE, Risk, Injury, Failure, Loss, and End-stage
Kidney Disease; SOFA, sequential organ failure assessment.
Table 5 | Stepwise analysis for prediction of failure to recover
renal function
Characteristic Model AUC (95% CI)
Age A 0.61 (0.53–0.70)
Serum creatinine on first day
of RIFLE F
B 0.72 (0.64–0.79)
PSI score on day 1 C 0.62 (0.54–0.70)
Maximum nonrenal SOFA score D 0.59 (0.50–0.67)
Plasma NGAL alone 0.74 (0.66–0.81)
A+B 0.73 (0.65–0.81)
A+B+C 0.73 (0.66–0.81)
A+B+C+D 0.78 (0.71–0.85)
A+pNGAL 0.74 (0.66–0.82)
B+pNGAL 0.76 (0.68–0.83)
C+pNGAL 0.73 (0.65–0.81)
D+pNGAL 0.77 (0.70–0.87)
A+B+C+D+pNGAL 0.80 (0.73–0.87)
Abbreviations: AUC, area under the curve; CI, confidence interval; pNGAL, plasma
neutrophil gelatinase-associated lipocalin; PSI, pneumonia severity index; RIFLE,
Risk, Injury, Failure, Loss, and End-stage Kidney Disease; SOFA, sequential organ
failure assessment.
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68% and specificity of 75% with a positive and negative
predictive value of 73% and 70%, respectively. When pNGAL
was combined with clinical variables, there was a 17%
improvement in reclassification of risk of not recovering renal
function. Most previous studies have tested pNGAL as
a marker for early diagnosis of AKI.16,18,20,24,26,28,30,31,35
However, to our knowledge, this is the first study to examine
the predictive value of pNGAL in recovery from pneumonia-
induced severe AKI.
Advanced age and higher clinical severity score were
associated with nonrecovery. These findings are not un-
expected and corresponded with the previous studies.1,9,36
However, for a given severity of AKI, those who did not
recover had higher serum creatinine on the first day of
RIFLE-F compared with those who recovered. This suggests
that faster rate of increase of serum creatinine in the
nonrecovery group might be because of higher severity
of illness or varying degrees of severity within the subgroup
of RIFLE-F.
We defined failure to recover as a composite outcome of
either death or dialysis or persistent RIFLE-F at hospital
discharge because of face validity, as recovery is not just for
renal outcome alone but for patient outcome as a whole.
Moreover, for early prognostication of patients with severe
AKI, we used first day of RIFLE-F to measure pNGAL
concentration and built prediction models around nonre-
covery rather than recovery. This has therapeutic implica-
tions such as to identify patients who are at risk for failure to
recover early and enroll a uniform cohort of patients who
are unlikely to recover in a biomarker-guided clinical trial of
severe AKI.
We found that a higher concentration of pNGAL was
associated with failure to recover following severe AKI.
This negative association with recovery could be related to
increased production, decreased elimination, or both.
Experimental and human studies indicate that NGAL is
present within the two distinct pools: systemic and renal.16
Higher pNGAL concentration in the systemic pool following
AKI may be because of three factors. First, increased NGAL
produced in the distant organs, especially a liver and lung
and its release into the circulation following AKI.37 Second,
NGAL production from the neutrophils, macrophages, and
other immune-competent cells.37 Third, the decreased
elimination of pNGAL because of a decrease in glomerular
filtration rate after AKI might have resulted in higher plasma
concentrations in our study.38
Currently, there is no definitive cutoff value for pNGAL
in the prediction nonrecovery. However, based on our result,
the cutoff for prediction of renal nonrecovery tends to
be higher than the usual cutoff value for prediction of
AKI.20,26,29,39,40 The higher pNGAL concentration might
reflect the higher severity of kidney injury and is a real-time
indicator of kidney dysfunction.38 This seems to be
confirmed by the correlation of pNGAL level with the
severity of illness and serum creatinine. In contrast, we found
no difference in IL-6 concentration by recovery, as well as
poor correlation between IL-6 and pNGAL, suggesting
that pNGAL is a unique marker for persistent kidney injury
than IL-6.
Overall, in our study the predictive value of pNGAL did
not improve when it was combined with the clinical model.
However, using IDI, the reclassification of risk of not
recovering improved by 17% when pNGAL was combined
with the clinical model.
There are several limitations to our study. First, we have
tested pNGAL at only single time point (on the first day of
RIFLE-F) and could not answer the predictive value of
pNGAL at other time points. Nevertheless, risk stratification
and prognostication using a biomarker is likely to be useful
only when biomarker concentrations are measured early.
Second, we were unable to measure process of care variables
such as the effect of cointerventions on biomarkers and its
influence on recovery. For instance, we were unable to assess
the influence of fluid resuscitation on pNGAL concentration
and recovery. Third, we found that nearly one-half of patients
with nonrecovery had died before hospital discharge.
Table 6 | Risk reclassification using pNGAL and clinical predictors compared with clinical predictors alone
Direction of reclassification
Model with clinical predictors alonea Model with clinical predictors + pNGAL Increased risk Decreased risk
Nonrecovery (n=85) o30% risk 30–60% risk 460% risk
o30% risk 7 (100) 0 0 9 (10.6) 7 (8.2)
30–60% risk 1 (2.8) 26 (72.2) 9 (25)
460% risk 0 6 (16.7) 36 (85.7)
Recovery (n=83) o30% risk 30–60% risk 4 60% risk
o30% risk 23 (85.1) 4 (14.8) 0 7 (8.4) 10 (12)
30–60% risk 8 (17.4) 35 (76.1) 3 (6.5)
460% risk 0 2 (20) 8 (80)
aClinical predictors include age, serum creatinine, pneumonia severity index, and maximum nonrenal SOFA score.
Data in shaded boxes (diagonals) represent similar risk classification between clinical model and clinical plus plasma neutrophil gelatinase-associated lipocalin (pNGAL
model). Numbers to the right of diagonals represent the patients who were reclassified as increased risk by adding pNGAL to the clinical model. Numbers to the left of the
diagonals represent patients who were reclassified as lower risk when pNGAL is added to the clinical model. Parentheses represent the percentage of reclassification in each
risk category.
The overall net reclassification index (NRI) for recovery and nonrecovery was calculated from the difference in proportions moving up and down among recovery and
nonrecovery (NRI=5.96% (95% confidence interval=7.4 to 19.35%), P=0.38). The relative integrated discrimination improvement (IDI) was measured for the increment in the
predicted probabilities for the subset experiencing renal nonrecovery and the decrement for the subset experiencing renal recovery (relative IDI=17.1%. P=0.01).
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We defined recovery to include survival, and hence death is
not a competing risk. However, we were unable to separate
recovery and death because of lack of cause-specific mortality
data. Nevertheless, differences in plasma NGAL concentra-
tions between recovery and nonrecovery groups persisted
when the analysis was restricted to survivors. Fourth, as a
post hoc analysis, our findings should be interpreted with caution,
tested, and validated in prospective studies. For instance, the first
day of RIFLE-F in order to measure pNGAL may not be
apparent clinically, unless baseline renal function of the patient is
known and serum creatinine is measured on a daily basis.
Our study has several strengths. First, as our study is the
first multicenter study of pNGAL concentration in the
adult population with pneumonia, our findings are highly
generalizable. Second, in the clinical practice, it is very
uncommon to know the onset of AKI except in some specific
situations such as post cardiac surgery or post radiocontrast
administration where the injury is predictable. However, in
our study, we tested pNGAL on the first day of RIFLE-F in a
homogenous cohort of patients with severe AKI: a popula-
tion at highest risk for nonrecovery. Third, we have chosen to
test blood, instead of urine, by the fact that (1) severe oliguria
is common in patients with severe sepsis and may preclude
the availability of urine, and (2) potentially confounding
alterations in urine biomarker concentrations can be induced
by volume status and diuretic therapy.
In summary, pNGAL appears to be a useful marker for
predicting renal nonrecovery following community-acquired
pneumonia. Our data suggest that pNGAL when used in
conjunction with clinical variables improves reclassification
of risk of renal nonrecovery, and augments clinical risk
prediction. Further research is warranted in a larger cohort
of patients with pneumonia-induced severe AKI to validate
our findings.
MATERIALS AND METHODS
Study design and participant selection
This study was a post hoc analysis performed as part of the GenIMS
(Genetic and Inflammatory Markers of Sepsis) study,41 which was a
large, multicenter, prospective, cohort study of subjects with
community-acquired pneumonia presenting to the emergency
departments of 28 teaching and nonteaching hospitals in the United
States between November 2001 and November 2003. Eligible criteria
were age X18 years and a clinical and radiological diagnosis of
community-acquired pneumonia using criteria by Fine et al.42
Exclusion criteria included transfer from another hospital, discharge
from an acute care hospital within the previous 10 days, pneumonia
within the previous 30 days, chronic dependency on mechanical
ventilation, cystic fibrosis, active pulmonary tuberculosis, admission
for palliative care, previous enrollment in the study, incarceration,
and pregnancy. The institutional review boards at all participating
sites approved the study, and we obtained written informed consent
from all participants or their proxies.
Definition of AKI and nonrecovery
AKI was classified according to the RIFLE criteria as proposed by the
Acute Dialysis Quality Initiative at any time during hospitaliza-
tion.43 The RIFLE stage was determined based on the worse of either
serial serum creatinine or urine output. Baseline creatinine was
defined by premorbid creatinine. For patients with no known
premorbid creatinine and no known medical history of chronic
kidney disease, we estimated premorbid creatinine using the
Modification of Diet in Renal Disease equation.44 Patients were
classified as stage Risk, if serum creatinine was 1.5 times the baseline
creatinine, or urine output o0.5 ml/kg/h for 6 h; stage Injury,
if serum creatinine was twice the baseline, or urine output
o0.5 ml/kg/h for 12 h; stage Failure, if serum creatinine was thrice
the baseline, or creatinineX4 mg/dl with an acute rise 40.5 mg/dl,
or urine output o0.3 ml/kg/h for 24 h, or anuria for 12 h.43
Of patients who developed RIFLE-F during hospitalization, recovery
was defined as a composite end point of being alive at discharge and
neither requiring renal replacement therapy during hospitalization
nor persistent RIFLE-F at hospital discharge.
The presence or absence of underlying disease before the onset of
pneumonia was defined by Charlson comorbidity index.45 Severe
sepsis was defined as pneumonia plus acute organ dysfunction
following the 2001 International Sepsis Definitions Conference
Criteria.46 Acute organ dysfunction was defined as a new SOFA score
following the European Society of Intensive Care Medicine sepsis
occurrence in the acutely ill patient study criteria.8 Pneumonia
Severity Index was measured according to criteria by Fine et al.42
APACHE III score was assessed on first hospital day regardless
of whether subject was admitted to intensive care unit or not.7
Biomarker assay
Plasma NGAL was tested only in subjects who developed severe AKI
and only on the first day of RIFLE-F using the Triage NGAL kit
(Alere, San Diego, CA), a point-of-care, fluorescence immunoassay,
or quantitative measurement of pNGAL and expressed as ng/ml.18
We measured IL-6 concentrations by chemiluminescent immuno-
assay using an automated analyzer (IMMULITE; Diagnostic Products,
Los Angeles, CA).41
Statistical analyses
We compared the baseline characteristics between patients who
recovered from AKI and those who failed to recover. Continuous
data were expressed as mean±s.d. and compared using the
Student’s t-test or Wilcoxon rank-sum test. Categorical data were
expressed as proportions and compared using the w2 test or Fisher’s
exact test. We fitted logistic regression models to evaluate the
association between pNGAL and failure to recover and generated
a receiver operating characteristic curve and calculated the AUC to
assess model discrimination. The optimal cutoff points were
determined by the largest sum of sensitivity and specificity.
To assess the additive prediction ability of pNGAL to the traditional
clinical predictors, we first identified the clinical prediction model
based on the AUC analysis and then added each marker individually
to this clinical model. The AUCs from the combined models were
compared with the AUC of the clinical model.
The increase in AUC due to the addition of a new significant
marker may be very small if the current clinical model already
includes important risk factors and has a reasonably good
discrimination.34,47,48 Therefore, we also calculated the IDI and
NRI using the methods suggested by Pencina et al.34 IDI is based on
the new model’s ability to improve integrated (average) sensitivity
without sacrificing average specificity. As the absolute IDI depends
on the event rate of the data, we used the relative IDI to reflect the
relative improvement. NRI focuses on reclassification tables
constructed separately for subjects with and without events based
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on predefined risk categories. We determined tertiles of risk
categories of o30, 30 to 60, and 460% risk a priori to reflect
low, intermediate, and high probability of nonrecovery.34 The NRI
was calculated as a measure to estimate any overall improvement in
reclassification with clinical variables and pNGAL instead of clinical
variable alone.34 All analyses were performed using SAS 9.0 (SAS
Institute, Cary, NC) at a significance level of 0.05.
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